Premium
A PHASE 1/2 STUDY OF MT‐3724 TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF MT‐3724 FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Author(s) -
Burnett C.A.,
Hamlin P.,
Dabovic K.,
Higgins J.,
Persky D.O.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.13_2632
Subject(s) - medicine , lymphoma , cd20 , diffuse large b cell lymphoma , refractory (planetary science) , immunotoxin , oncology , population , cancer research , immunology , antibody , monoclonal antibody , biology , environmental health , astrobiology